Nicholas A Meanwell

List of Publications by Year
in descending order

283 papers	18,230 citations	30070 54 h-index	15266 126 g-index
339 all docs	339 docs citations	339 times ranked	16687 citing authors

#	Article	IF	Citations
1	Advances in the synthesis of three-dimensional molecular architectures by dearomatizing photocycloadditions. Tetrahedron, 2022, 103, 132087.	1.9	12
2	GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0187621.	3.2	13
3	Design, Synthesis, and Preclinical Profiling of GSK3739936 (BMS-986180), an Allosteric Inhibitor of HIV-1 Integrase with Broad-Spectrum Activity toward 124/125 Polymorphs. Journal of Medicinal Chemistry, 2022, 65, 4949-4971.	6.4	10
4	The Genesis and Future Prospects of Small Molecule HIV-1 Attachment Inhibitors. Advances in Experimental Medicine and Biology, 2022, 1366, 45-64.	1.6	1
5	Discovery and Preclinical Profiling of GSK3839919, a Potent HIV-1 Allosteric Integrase Inhibitor. ACS Medicinal Chemistry Letters, 2022, 13, 972-980.	2.8	9
6	Scaffold modifications to the 4-(4,4-dimethylpiperidinyl) 2,6-dimethylpyridinyl class of HIV-1 allosteric integrase inhibitors. Bioorganic and Medicinal Chemistry, 2022, 67, 116833.	3.0	3
7	Applications of Isosteres of Piperazine in the Design of Biologically Active Compounds: Part 1. Journal of Agricultural and Food Chemistry, 2022, 70, 10942-10971.	5.2	22
8	Applications of Isosteres of Piperazine in the Design of Biologically Active Compounds: Part 2. Journal of Agricultural and Food Chemistry, 2022, 70, 10972-11004.	5.2	15
9	Ligandâ€Enabled Î²â€C(sp³)âˆ'H Lactamization of Tosylâ€Protected Aliphatic Amides Using a Practical Oxidant. Angewandte Chemie - International Edition, 2022, 61, .	13.8	12
10	Design and exploration of C-3 benzoic acid bioisosteres and alkyl replacements in the context of GSK3532795 (BMS-955176) that exhibit broad spectrum HIV-1 maturation inhibition. Bioorganic and Medicinal Chemistry Letters, 2021, 36, 127823.	2.2	7
11	Azatricyclic Inverse Agonists of RORÎ³t That Demonstrate Efficacy in Models of Rheumatoid Arthritis and Psoriasis. ACS Medicinal Chemistry Letters, 2021, 12, 827-835.	2.8	3
12	Utilization of C(sp³)â€Carboxylic Acids and Their Redoxâ€Active Esters in Decarboxylative Carbonâ€'Carbon Bond Formation. Advanced Synthesis and Catalysis, 2021, 363, 3693-3736.	4.3	64
13	Simplifying Submission Requirements for the Journal of Medicinal Chemistry. Journal of Medicinal Chemistry, 2021, 64, 7877-7878.	6.4	0
14	Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design. Journal of Medicinal Chemistry, 2021, 64, 9786-9874.	6.4	29
15	Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir. Medicinal Chemistry Research, 2021, 30, 1-26.	2.4	4
16	Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design. Journal of Medicinal Chemistry, 2021, 64, 14046-14128.	6.4	171
17	A survey of applications of tetrahydropyrrolo-3,4-azoles and tetrahydropyrrolo-2,3-azoles in medicinal chemistry. Advances in Heterocyclic Chemistry, 2021, , 31-100.	1.7	6
18	Photocatalytic Dearomative Intermolecular [2 + 2] Cycloaddition of Heterocycles for Building Molecular Complexity. Journal of Organic Chemistry, 2021, 86, 1730-1747.	3.2	45

#	Article	IF	Citations
19	Facile Access to 1,4-Disubstituted Pyrrolo[1,2-a]pyrazines from Î±-Aminoacetonitriles. Synthesis, 2020, 52, 441-449.	2.3	2
20	Intramolecular [2+2] Cycloaddition of Nâ€Allylcinnamamines and Nâ€Allylcinnamamides by Visibleâ€Light Photocatalysis. European Journal of Organic Chemistry, 2020, 2020, 41-46.	2.4	16
21	Applications of fluorine-containing amino acids for drug design. European Journal of Medicinal Chemistry, 2020, 186, 111826.	5.5	150
22	Heterocycle amide isosteres: An approach to overcoming resistance for HIV-1 integrase strand transfer inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126784.	2.2	7
23	Cyclic tailor-made amino acids in the design of modern pharmaceuticals. European Journal of Medicinal Chemistry, 2020, 208, 112736.	5.5	39
24	Structure-based amelioration of PXR transactivation in a novel series of macrocyclic allosteric inhibitors of HIV-1 integrase. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127531.	2.2	6
25	Epigenetics 2.0: Special Issue on Epigeneticsâ€"Call for Papers. Journal of Medicinal Chemistry, 2020, 63, 12129-12130.	6.4	1
26	Design, synthesis and SAR study of novel C2-pyrazolopyrimidine amides and amide isosteres as allosteric integrase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127516.	2.2	6
27	Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection. Journal of Medicinal Chemistry, 2020, 63, 14740-14760.	6.4	12
28	Advances toward COVID-19 Therapies Special Issue Call for Papers. Journal of Medicinal Chemistry, 2020, 63, 15073-15074.	6.4	1
29	Writing Your Next Medicinal Chemistry Article: Journal Bibliometrics and Guiding Principles for Industrial Authors. Journal of Medicinal Chemistry, 2020, 63, 14336-14356.	6.4	5
30	(Carbonyl)oxyalkyl linker-based amino acid prodrugs of the HIV-1 protease inhibitor atazanavir that enhance oral bioavailability and plasma trough concentration. European Journal of Medicinal Chemistry, 2020, 207, 112749.	5.5	5
31	Frontispiece: Tailorâ€Made Amino Acids and Fluorinated Motifs as Prominent Traits in Modern Pharmaceuticals. Chemistry - A European Journal, 2020, 26, .	3.3	2
32	The 2020 Nobel Prize in Physiology or Medicine. Journal of Medicinal Chemistry, 2020, 63, 13197-13204.	6.4	5
33	Tailorâ€Made Amino Acids and Fluorinated Motifs as Prominent Traits in Modern Pharmaceuticals. Chemistry - A European Journal, 2020, 26, 11349-11390.	3.3	81
34	Introduction: Drug Metabolism and Toxicology Special Issue. Journal of Medicinal Chemistry, 2020, 63, 6249-6250.	6.4	2
35	Multigram Synthesis of BMS-929075, an Allosteric, Palm Site Inhibitor of HCV NS5B Replicase, Involving the Synthesis of a Highly Functionalized Benzofuran through a Telescoped Process. Organic Process Research and Development, 2020, 24, 1157-1163.	2.7	10
36	Metabolic and Pharmaceutical Aspects of Fluorinated Compounds. Journal of Medicinal Chemistry, 2020, 63, 6315-6386.	6.4	358

#	Article	IF	Citations
37	Artificial Intelligence in Drug Discovery: Into the Great Wide Open. Journal of Medicinal Chemistry, 2020, 63, 8651-8652.	6.4	40
38	Discovery and Optimization of Novel Pyrazolopyrimidines as Potent and Orally Bioavailable Allosteric HIV-1 Integrase Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 2620-2637.	6.4	21
39	Synthesis of Cyclobutane-Fused Tetracyclic Scaffolds via Visible-Light Photocatalysis for Building Molecular Complexity. Journal of the American Chemical Society, 2020, 142, 3094-3103.	13.7	92
40	Design, synthesis and SAR study of bridged tricyclic pyrimidinone carboxamides as HIV-1 integrase inhibitors. Bioorganic and Medicinal Chemistry, 2020, 28, 115541.	3.0	6
41	The Discovery and Early Clinical Evaluation of the HCV NS3/4A Protease Inhibitor Asunaprevir (BMS-650032). Topics in Medicinal Chemistry, 2019, , 317-354.	0.8	1
42	In Praise of Remarkably Powerful Centamolecular Therapeutic Agents. ACS Medicinal Chemistry Letters, 2019, 10, 1094-1097.	2.8	8
43	Design, Synthesis, and Pharmacokinetic Evaluation of Phosphate and Amino Acid Ester Prodrugs for Improving the Oral Bioavailability of the HIV-1 Protease Inhibitor Atazanavir. Journal of Medicinal Chemistry, 2019, 62, 3553-3574.	6.4	26
44	A survey of core replacements in indole-based HIV-1 attachment inhibitors. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1423-1429.	2.2	16
45	Second Generation Inhibitors of HIV-1 Maturation. ACS Medicinal Chemistry Letters, 2019, 10, 287-294.	2.8	14
46	The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex. Topics in Medicinal Chemistry, 2019, , 27-55.	0.8	5
47	Allosteric Modulators of Drug Targets. Journal of Medicinal Chemistry, 2019, 62, 1-2.	6.4	4
48	Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective Na_V1.7 Inhibitors for the Treatment of Pain. Journal of Medicinal Chemistry, 2019, 62, 831-856.	6.4	19
49	5,6,7,8-Tetrahydro-1,6-naphthyridine Derivatives as Potent HIV-1-Integrase-Allosteric-Site Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 1348-1361.	6.4	32
50	Discovery of new indole-based acylsulfonamide Nav1.7 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 659-663.	2.2	6
51	Coupling of an Acyl Migration Prodrug Strategy with Bio-activation To Improve Oral Delivery of the HIV-1 Protease Inhibitor Atazanavir. Journal of Medicinal Chemistry, 2018, 61, 4176-4188.	6.4	11
52	P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1853-1859.	2.2	8
53	The design, synthesis and structure-activity relationships associated with C28 amine-based betulinic acid derivatives as inhibitors of HIV-1 maturation. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 1550-1557.	2.2	18
54	Discovery of morpholine-based aryl sulfonamides as Na v 1.7 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 958-962.	2.2	9

#	Article	IF	Citations
55	Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design. Journal of Medicinal Chemistry, 2018, 61, 5822-5880.	6.4	1,524
56	Allosteric Modulators of Drug Targets Special Issue. Journal of Medicinal Chemistry, 2018, 61, 1381-1381.	6.4	0
57	Potent Inhibitors of Hepatitis C Virus NS3 Protease: Employment of a Difluoromethyl Group as a Hydrogen-Bond Donor. ACS Medicinal Chemistry Letters, 2018, 9, 143-148.	2.8	30
58	Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir. Journal of Medicinal Chemistry, 2018, 61, 62-80.	6.4	98
59	In This Issue, Volume 9, Issue 1. ACS Medicinal Chemistry Letters, 2018, 9, 1-1.	2.8	0
60	The expanding role of prodrugs in contemporary drug design and development. Nature Reviews Drug Discovery, 2018, 17, 559-587.	46.4	478
61	Bioactivation of cyclopropyl rings by P450: an observation encountered during the optimisation of a series of hepatitis C virus NS5B inhibitors. Xenobiotica, 2018, 48, 1215-1226.	1.1	9
62	Structureâ€“Property Basis for Solving Transporter-Mediated Efflux and Pan-Genotypic Inhibition in HCV NS5B Inhibitors. ACS Medicinal Chemistry Letters, 2018, 9, 1217-1222.	2.8	2
63	The discovery and preclinical evaluation of BMS-707035, a potent HIV-1 integrase strand transfer inhibitor. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2124-2130.	2.2	12
64	Design, Synthesis, and SAR of C-3 Benzoic Acid, C-17 Triterpenoid Derivatives. Identification of the HIV-1 Maturation Inhibitor 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-3a-((2-(1,1-Dioxidothiom Acid (GSK3532795, BMS-955176). Journal of Medicinal Chemistry, 2018, 61, 7289-7313.	6.4	23
65	Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir. Journal of Medicinal Chemistry, 2018, 61, 6308-6327.	6.4	34
66	The discovery and optimization of naphthalene-linked P2-P4 Macrocycles as inhibitors of HCV NS3 protease. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 43-48.	2.2	4
67	A Synopsis of the Properties and Applications of Heteroaromatic Rings in Medicinal Chemistry. Advances in Heterocyclic Chemistry, 2017, , 245-361.	1.7	31
68	Development of New Benzenesulfonamides As Potent and Selective Na_v1.7 Inhibitors for the Treatment of Pain. Journal of Medicinal Chemistry, 2017, 60, 2513-2525.	6.4	32
69	The discovery of a pan-genotypic, primer grip inhibitor of HCV NS5B polymerase. MedChemComm, 2017, 8, 796-806.	3.4	11
70	Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies. Journal of Medicinal Chemistry, 2017, 60, 4369-4385.	6.4	26
71	Discovery of BMS-961955, an allosteric inhibitor of the hepatitis C virus NS5B polymerase. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3294-3300.	2.2	5
72	Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 590-596.	2.2	5

#	Article	IF	Citations
73	Functionalized triazines as potent HCV entry inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1089-1093.	2.2	4
74	Development of the Large-Scale Synthesis of Tetrahydropyran Glycine, a Precursor to the HCV NS5A Inhibitor BMS-986097. Journal of Organic Chemistry, 2017, 82, 10376-10387.	3.2	8
75	Design strategies in the prodrugs of HIV-1 protease inhibitors to improve the pharmaceutical properties. European Journal of Medicinal Chemistry, 2017, 139, 865-883.	5.5	27
76	Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation. Bioorganic and Medicinal Chemistry, 2017, 25, 5490-5505.	3.0	19
77	Drug-target interactions that involve the replacement or displacement of magnesium ions. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 5355-5372.	2.2	7
78	Improving Metabolic Stability with Deuterium: The Discovery of BMT-052, a Pan-genotypic HCV NS5B Polymerase Inhibitor. ACS Medicinal Chemistry Letters, 2017, 8, 771-774.	2.8	24
79	Journal of Medicinal Chemistry, Technological Advances: Highlights 2015â€“2016. Journal of Medicinal Chemistry, 2017, 60, 1-3.	6.4	4
80	Discovery and initial optimization of alkoxyanthranilic acid derivatives as inhibitors of HCV NS5B polymerase. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 295-298.	2.2	5
81	C-3 benzoic acid derivatives of C-3 deoxybetulinic acid and deoxybetulin as HIV-1 maturation inhibitors. Bioorganic and Medicinal Chemistry, 2016, 24, 1757-1770.	3.0	24
82	Discovery of BMS-955176, a Second Generation HIV-1 Maturation Inhibitor with Broad Spectrum Antiviral Activity. ACS Medicinal Chemistry Letters, 2016, 7, 568-572.	2.8	45
83	Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage. Antimicrobial Agents and Chemotherapy, 2016, 60, 3956-3969.	3.2	58
84	2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. Journal of Medicinal Chemistry, 2016, 59, 7311-7351.	6.4	35
85	Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing. Journal of Medicinal Chemistry, 2016, 59, 8042-8060.	6.4	24
86	Inhibitors of HIV-1 maturation: Development of structureâ€“activity relationship for C-28 amides based on C-3 benzoic acid-modified triterpenoids. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1925-1930.	2.2	32
87	Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space. Chemical Research in Toxicology, 2016, 29, 564-616.	3.3	148
88	Discovery and preclinical evaluation of potent, orally bioavailable, metabolically stable cyclopropylindolobenzazepine acylsulfonamides as thumb site 1 inhibitors of the hepatitis c virus NS5B RNA-dependent, RNA polymerase. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 936-940.	2.2	9
89	Synergistic Activity of Combined NS5A Inhibitors. Antimicrobial Agents and Chemotherapy, 2016, 60, 1573-1583.	3.2	7
90	Inhibitors of HIV-1 attachment: The discovery and structureâ€“activity relationships of tetrahydroisoquinolines as replacements for the piperazine benzamide in the 3-glyoxylyl 6-azaindole pharmacophore. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 160-167.	2.2	23

#	Article	IF	Citations
91	Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors. PLoS Pathogens, 2016, 12, e1005990.	4.7	19
92	Case History: The Discovery of the First Hepatitis C Virus NS5A Replication Complex Inhibitor Daclatasvir (Daklinzaâ„¢). Medicinal Chemistry Reviews, 2016, , 375-397.	0.1	1
93	A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design. Journal of Medicinal Chemistry, 2015, 58, 4383-4438.	6.4	582
94	Applications of Fluorine in Medicinal Chemistry. Journal of Medicinal Chemistry, 2015, 58, 8315-8359.	6.4	2,464
95	Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A. Nature, 2015, 527, 245-248.	27.8	44
96	Homology models of the <scp>HIV</scp>â€1 attachment inhibitor <scp>BMS</scp>â€626529 bound to gp120 suggest a unique mechanism of action. Proteins: Structure, Function and Bioinformatics, 2015, 83, 331-350.	2.6	47
97	Tactics in Contemporary Drug Design. Topics in Medicinal Chemistry, 2015, , .	0.8	18
98	Synthesis and evaluation of C2-carbon-linked heterocyclic-5-hydroxy-6-oxo-dihydropyrimidine-4-carboxamides as HIV-1 integrase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 717-720.	2.2	32
99	The Practice of Medicinal Chemistry and its Contributions to Therapy. Medicinal Chemistry Reviews, 2015, , 359-393.	0.1	2
100	The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection. Journal of Medicinal Chemistry, 2014, 57, 1730-1752.	6.4	101
101	The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors. Protein Science, 2014, 23, 723-734.	7.6	96
102	Enabled clinical use of an HIV-1 attachment inhibitor through drug delivery. Drug Discovery Today, 2014, 19, 1288-1293.	6.4	13
103	Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 1643-1672.	6.4	68
104	Identification of a novel series of potent HCV NS5B Site I inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1993-1997.	2.2	5
105	Hepatitis C Virus NS5A Replication Complex Inhibitors. Part 6: Discovery of a Novel and Highly Potent Biarylimidazole Chemotype with Inhibitory Activity Toward Genotypes 1a and 1b Replicons. Journal of Medicinal Chemistry, 2014, 57, 1995-2012.	6.4	22
106	Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase. Journal of Medicinal Chemistry, 2014, 57, 1855-1879.	6.4	83
107	Introduction to Hepatitis C Virus (HCV) Therapies Special Thematic Issue. Journal of Medicinal Chemistry, 2014, 57, 1625-1626.	6.4	10
108	Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection. Journal of Medicinal Chemistry, 2014, 57, 1708-1729.	6.4	61

#	Article	IF	Citations
109	Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir. Journal of Medicinal Chemistry, 2014, 57, 2013-2032.	6.4	74
110	Tactical Applications of Fluorine in Drug Design and Development. , 2014, , 1-54.		10
111	Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of Hepatitis C Virus NS5B Polymerase. Antimicrobial Agents and Chemotherapy, 2014, 58, 3485-3495.	3.2	56
112	A practical and efficient synthesis of 6-carboalkoxy-13-cycloalkyl-5H-indolo[2,1-a][2]benzazepine-10-carboxylic acid derivatives. Tetrahedron Letters, 2014, 55, 1148-1153.	1.4	9
113	Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect. Journal of Medicinal Chemistry, 2014, 57, 5057-5071.	6.4	96
114	HCV NS5A Replication Complex Inhibitors. Part 4.1 Optimization for Genotype 1a Replicon Inhibitory Activity. Journal of Medicinal Chemistry, 2014, 57, 1976-1994.	6.4	28
115	Characterizations of HCV NS5A replication complex inhibitors. Virology, 2013, 444, 343-354.	2.4	44
116	Inhibitors of HIV-1 attachment. Part 11: The discovery and structureâ€“activity relationships associated with 4,6-diazaindole cores. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 218-222.	2.2	18
117	Inhibitors of HIV-1 attachment. Part 10. The discovery and structureâ€“activity relationships of 4-azaindole cores. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 213-217.	2.2	29
118	Evaluation of HIV-1 inhibition by stereoisomers and analogues of the sesquiterpenoid hydroquinone peyssonol A. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 2192-2196.	2.2	9
119	Inhibitors of HIV-1 attachment. Part 7: Indole-7-carboxamides as potent and orally bioavailable antiviral agents. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 198-202.	2.2	46
120	A scalable synthesis of (1R,3S,5R)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid. Tetrahedron Letters, 2013, 54, 6722-6724.	1.4	12
121	Inhibitors of hERG Channel Trafficking. Annual Reports in Medicinal Chemistry, 2013, 48, 335-352.	0.9	0
122	Inhibitors of HIV-1 attachment. Part 9: An assessment of oral prodrug approaches to improve the plasma exposure of a tetrazole-containing derivative. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 209-212.	2.2	27
123	The Influence of Bioisosteres in Drug Design: Tactical Applications to Address Developability Problems. Topics in Medicinal Chemistry, 2013, , 283-381.	0.8	30
124	HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic glycinamide cap derivatives. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4428-4435.	2.2	17
125	Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Attachment. 12. Structureâ€“Activity Relationships Associated with 4-Fluoro-6-azaindole Derivatives Leading to the Identification of 1-(4-Benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-585248). Journal of Medicinal Chemistry, 2013, 56, 1656-1669.	6.4	47
126	Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Attachment 13. Synthesis and Profiling of a Novel Amminium Prodrug of the HIV-1 Attachment Inhibitor BMS-585248. Journal of Medicinal Chemistry, 2013, 56, 1670-1676.	6.4	9

#	Article	IF	Citations
127	HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 779-784.	2.2	29
128	Inhibitors of HIV-1 attachment. Part 8: The effect of C7-heteroaryl substitution on the potency, and in vitro and in vivo profiles of indole-based inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 203-208.	2.2	36
129	In VitroAntiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068. Antimicrobial Agents and Chemotherapy, 2012, 56, 3498-3507.	3.2	118
130	Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrobial Agents and Chemotherapy, 2012, 56, 5387-5396.	3.2	173
131	Protein-Protein Interaction Targets to Inhibit HIV-1 Infection. Topics in Medicinal Chemistry, 2012, , 105-165.	0.8	0
132	Inhibitors of Protein-Protein Interactions in Paramyxovirus Fusion: A Focus on Respiratory Syncytial Virus. Topics in Medicinal Chemistry, 2012, , 167-196.	0.8	3
133	HCV NS5A replication complex inhibitors. Part 2: Investigation of stilbene prolinamides. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6063-6066.	2.2	27
134	Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Attachment 6. Preclinical and Human Pharmacokinetic Profiling of BMS-663749, a Phosphonooxymethyl Prodrug of the HIV-1 Attachment Inhibitor 2-(4-Benzoyl-1-piperazinyl)-1-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxoethanone (BMS-488043). Journal of Medicinal Chemistry, 2012, 55, 2048-2056.	6.4	49
135	Chemistry in the Pharmaceutical Industry. , 2012, , 391-418.		0
136	The NS5A Replication Complex Inhibitors: Difference Makers?. Clinics in Liver Disease, 2011, 15, 627-639.	2.1	28
137	Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes. ACS Medicinal Chemistry Letters, 2011, 2, 224-229.	2.8	79
138	Improving Drug Candidates by Design: A Focus on Physicochemical Properties As a Means of Improving Compound Disposition and Safety. Chemical Research in Toxicology, 2011, 24, 1420-1456.	3.3	450
139	New first and second generation inhibitors of human immunodeficiency virus-1 integrase. Expert Opinion on Therapeutic Patents, 2011, 21, 1173-1189.	5.0	51
140	Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design. Journal of Medicinal Chemistry, 2011, 54, 2529-2591.	6.4	2,216
141	Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 15366-15371.	7.1	116
142	Discovery of Potent Hepatitis C Virus NS5A Inhibitors with Dimeric Structures. Antimicrobial Agents and Chemotherapy, 2011, 55, 3795-3802.	3.2	51
143	The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization. Journal of General Virology, 2011, 92, 2502-2511.	2.9	57
144	Hepatitis C Virusâ€"Progress Toward Inhibiting the Nonenzymatic Viral Proteins. Annual Reports in Medicinal Chemistry, 2011, , 263-282.	0.9	4

#	Article	IF	Citations
145	Utilization of in vitro Cacoâ€2 permeability and liver microsomal halfâ€life screens in discovering BMSâ€488043, a novel HIVâ€1 attachment inhibitor with improved pharmacokinetic properties. Journal of Pharmaceutical Sciences, 2010, 99, 2135-2152.	3.3	15
146	(Z)-2,2-Dimethyl-5-carboxymethylene-1,3-dioxolan-4-one: a new synthon for the synthesis of Î±,Î³-diketoacid derivatives. Tetrahedron Letters, 2010, 51, 3170-3173.	1.4	2
147	Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature, 2010, 465, 96-100.	27.8	882
148	A Novel Small Molecule Inhibitor of Hepatitis C Virus Entry. PLoS Pathogens, 2010, 6, e1001086.	4.7	79
149	Identification of Hepatitis C Virus NS5A Inhibitors. Journal of Virology, 2010, 84, 482-491.	3.4	182
150	Solid Phase Synthesis of Novel Pyrrolidinedione Analogs as Potent HIV-1 Integrase Inhibitors. ACS Combinatorial Science, 2010, 12, 84-90.	3.3	23
151	The alkylation of isatinâ€derived oximes: Spectroscopic and Xâ€ray crystallographic structural characterization of oxime and nitrone products. Journal of Heterocyclic Chemistry, 2009, 46, 432-442.	2.6	16
152	Inhibitors of HIV-1 attachment. Part 2: An initial survey of indole substitution patterns. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1977-1981.	2.2	58
153	Inhibitors of HIV-1 attachment. Part 4: A study of the effect of piperazine substitution patterns on antiviral potency in the context of indole-based derivatives. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5140-5145.	2.2	49
154	Respiratory syncytial virus fusion inhibitors. Part 7: Structureâ€“activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4857-4862.	2.2	39
155	Inhibitors of HIV-1 attachment. Part 3: A preliminary survey of the effect of structural variation of the benzamide moiety on antiviral activity. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5136-5139.	2.2	38
156	Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Attachment. 5. An Evolution from Indole to Azaindoles Leading to the Discovery of 1-(4-Benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a Drug Candidate That Demonstrates Antiviral Activity in HIV-1-Infected Subjects. Journal of Medicinal Chemistry, 2009, 52, 7778-7787.	6.4	98
157	Chapter 20 Progress towards the Discovery and Development of Specifically Targeted Inhibitors of Hepatitis C Virus. Annual Reports in Medicinal Chemistry, 2009, , 397-440.	0.9	9
158	Influenza--the case for combination therapy. Current Opinion in Investigational Drugs, 2009, 10, 746-9.	2.3	3
159	Inhibition of hERG Channel Trafficking: An Underâ€Explored Mechanism for Drugâ€Induced QT Prolongation. ChemMedChem, 2008, 3, 1501-1502.	3.2	12
160	The Emerging Utility of Co-Crystals in Drug Discovery and Development. Annual Reports in Medicinal Chemistry, 2008, 43, 373-404.	0.9	22
161	2007: a difficult year for HCV drug development. Current Opinion in Investigational Drugs, 2008, 9, 128-31.	2.3	2
162	Recent Developments in the Virology and Antiviral Research of Severe Acute Respiratory Syndrome Coronavirus. Infectious Disorders - Drug Targets, 2007, 7, 29-41.	0.8	11

#	Article	IF	Citations
163	3-[(5-Chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one, BMS-191011:Â Opener of Large-Conductance Ca2+-Activated Potassium (Maxi-K) Channels, Identification, Solubility, and SAR. Journal of Medicinal Chemistry, 2007, 50, 528-542.	6.4	51
164	Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 895-901.	2.2	63
165	Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4592-4598.	2.2	32
166	Benzyl amide-ketoacid inhibitors of HIV-integrase. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4886-4890.	2.2	14
167	Respiratory syncytial virus fusion inhibitors. Part 6: An examination of the effect of structural variation of the benzimidazol-2-one heterocycle moiety. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4784-4790.	2.2	38
168	Respiratory syncytial virus - The discovery and optimization of orally bioavailable fusion inhibitors. Drugs of the Future, 2007, 32, 441.	0.1	21
169	Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. Current Opinion in Investigational Drugs, 2007, 8, 669-81.	2.3	39
170	Respiratory syncytial virus fusion inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1115-1122.	2.2	38
171	Triketoacid inhibitors of HIV-integrase: A new chemotype useful for probing the integrase pharmacophore. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2920-2924.	2.2	29
172	Exploration of the diketoacid integrase inhibitor chemotype leading to the discovery of the anilide-ketoacids chemotype. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5818-5821.	2.2	8
173	An effective procedure for the preparation of 3-substituted-4- or 6-azaindoles from ortho-methyl nitro pyridines. Tetrahedron Letters, 2006, 47, 5653-5656.	1.4	22
174	Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention. Medicinal Research Reviews, 2006, 26, 414-433.	10.5	26
175	A Facile Synthesis of 1-Substituted Cyclopropylsulfonamides. Synlett, 2006, 2006, 0725-0728.	1.8	15
176	Hepatitis C virus entry: an intriguing challenge for drug discovery. Current Opinion in Investigational Drugs, 2006, 7, 727-32.	2.3	6
177	A base-catalyzed, direct synthesis of 3,5-disubstituted 1,2,4-triazoles from nitriles and hydrazides. Tetrahedron Letters, 2005, 46, 3429-3432.	1.4	83
178	A one-pot synthesis of nitrogen-containing heteroaryl Î±-keto amides from heteroaryl halides. Tetrahedron Letters, 2005, 46, 3587-3589.	1.4	21
179	Synthesis of substituted aryl amidines from aminoacetonitriles. Tetrahedron Letters, 2005, 46, 4919-4923.	1.4	6
180	Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics. Biopharmaceutics and Drug Disposition, 2005, 26, 387-402.	1.9	36

#	Article	IF	Citations
181	A Base-Catalyzed, Direct Synthesis of 3,5-Disubstituted 1,2,4-Triazoles from Nitriles and Hydrazides.. ChemInform, 2005, 36, no.	0.0	0
182	A One-Pot Synthesis of Nitrogen-Containing Heteroaryl Î±-Keto Amides from Heteroaryl Halides.. ChemInform, 2005, 36, no.	0.0	0
183	Synthesis of Substituted Aryl Amidines from Aminoacetonitriles.. ChemInform, 2005, 36, no.	0.0	0
184	Developments in Antiviral Drug Design, Discovery and Development in 2004. Current Drug Targets Infectious Disorders, 2005, 5, 307-400.	2.1	4
185	Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor. Journal of Antimicrobial Chemotherapy, 2005, 55, 289-292.	3.0	61
186	Azole-N-Acetonitriles as Carbonyl Synthons: A One-Pot Preparation of ÂHeteroaryl Amides from Halides. Synlett, 2004, 2004, 2323-2326.	1.8	3
187	Oral Efficacy of a Respiratory Syncytial Virus Inhibitor in Rodent Models of Infection. Antimicrobial Agents and Chemotherapy, 2004, 48, 2448-2454.	3.2	73
188	Targeting a binding pocket within the trimer-of-hairpins: Small-molecule inhibition of viral fusion. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15046-15051.	7.1	102
189	Selective Monoacylation of Symmetrical Diamines via Prior Complexation with Boron.. ChemInform, 2004, 35, no.	0.0	1
190	Respiratory Syncytial Virus Inhibitors. Part 2. Benzimidazol-2-one Derivatives. ChemInform, 2004, 35, no.	0.0	0
191	Dialkylaminoacetonitrile Derivatives as Amide Synthons. A One-Pot Preparation of Heteroaryl Amides via a Strategy of Sequential SNAr Substitution and Oxidation.. ChemInform, 2004, 35, no.	0.0	0
192	Acetonitrile Derivatives as Carbonyl Synthons. One-Pot Preparation of Diheteroaryl Ketones via a Strategy of Sequential SNAr Substitution and Oxidation.. ChemInform, 2004, 35, no.	0.0	0
193	Malononitrile as a Carbonyl Synthon: A One-Pot Preparation of Heteroaryl Amide via a SNAr-Oxidationâ€"Displacement Strategy.. ChemInform, 2004, 35, no.	0.0	0
194	Respiratory syncytial virus inhibitors. Part 2: Benzimidazol-2-one derivatives. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 1133-1137.	2.2	35
195	Novel 3â€²-deoxy analogs of the anti-HBV agent entecavir: synthesis of enantiomers from a single chiral epoxide. Tetrahedron Letters, 2004, 45, 739-742.	1.4	35
196	Malononitrile as a carbonyl synthon: a one-pot preparation of heteroaryl amide via a S N Ar-oxidationâ€"displacement strategy. Tetrahedron Letters, 2004, 45, 5909-5911.	1.4	7
197	Acetonitrile Derivatives as Carbonyl Synthons. One-Pot Preparation of Diheteroaryl Ketones via a Strategy of Sequential SNAr Substitution and Oxidation. Journal of Organic Chemistry, 2004, 69, 1364-1367.	3.2	28
198	Dialkylaminoacetonitrile Derivatives as Amide Synthons. A One-Pot Preparation of Heteroaryl Amides via a Strategy of Sequential SNAr Substitution and Oxidation. Journal of Organic Chemistry, 2004, 69, 1360-1363.	3.2	32

#	Article	IF	Citations
199	Orally Active Fusion Inhibitor of Respiratory Syncytial Virus. Antimicrobial Agents and Chemotherapy, 2004, 48, 413-422.	3.2	136
200	Discovery of 4-Benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806):Â A Novel HIV-1 Attachment Inhibitor That Interferes with CD4-gp120 Interactionsâ€. Journal of Medicinal Chemistry, 2003, 46, 4236-4239.	6.4	206
201	Development of a photoaffinity label for respiratory syncytial virus inhibitors. Journal of Labelled Compounds and Radiopharmaceuticals, 2003, 46, 1105-1116.	1.0	7
202	An Effective Procedure for the Acylation of Azaindoles at C-3.. ChemInform, 2003, 34, no.	0.0	0
203	Novel Openers of Ca2+-Dependent Large-Conductance Potassium Channels: Symmetrical Pharmacophore and Electrophysiological Evaluation of Bisphenols.. ChemInform, 2003, 34, no.	0.0	0
204	Fundamental Structureâ€"Activity Relationships Associated with a New Structural Class of Respiratory Syncytial Virus Inhibitor.. ChemInform, 2003, 34, no.	0.0	0
205	Fundamental structureâ€“Activity relationships associated with a new structural class of respiratory syncytial virus inhibitor. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2141-2144.	2.2	61
206	Novel Openers of Ca2+-Dependent Large-Conductance Potassium Channels: Symmetrical Pharmacophore and Electrophysiological Evaluation of Bisphenols. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 1437-1439.	2.2	19
207	Selective Monoacylation of Symmetrical Diamines via Prior Complexation with Boron. Organic Letters, 2003, 5, 3399-3402.	4.6	35
208	Biochemical and Genetic Characterizations of a Novel Human Immunodeficiency Virus Type 1 Inhibitor That Blocks gp120-CD4 Interactions. Journal of Virology, 2003, 77, 10528-10536.	3.4	166
209	A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11013-11018.	7.1	339
210	Chapter 22. Non-HIV antiviral agents. Annual Reports in Medicinal Chemistry, 2003, 38, 213-228.	0.9	1
211	Hepatitis C virus NS3 serine protease as a drug discovery target. Drugs of the Future, 2003, 28, 465.	0.1	10
212	Inhibitors of the entry of HIV into host cells. Current Opinion in Drug Discovery & Development, 2003, 6, 451-61.	1.9	10
213	Chapter 14. Antiviral agents. Annual Reports in Medicinal Chemistry, 2002, 37, 133-147.	0.9	1
214	4,5-Diphenyltriazol-3-ones:Â Openers of Large-Conductance Ca2+-Activated Potassium (Maxi-K) Channels. Journal of Medicinal Chemistry, 2002, 45, 2942-2952.	6.4	38
215	A General Method for the Preparation of 4- and 6-Azaindoles. Journal of Organic Chemistry, 2002, 67, 2345-2347.	3.2	66
216	An Effective Procedure for the Acylation of Azaindoles at C-3. Journal of Organic Chemistry, 2002, 67, 6226-6227.	3.2	51

#	Article	IF	Citations
217	Synthesis and Structureâ"Activity Relationships of 3-Aryloxindoles:â€‰ A New Class of Calcium-Dependent, Large Conductance Potassium (Maxi-K) Channel Openers with Neuroprotective Properties. Journal of Medicinal Chemistry, 2002, 45, 1487-1499.	6.4	171
218	A Strategy for the Synthesis of Aryl Î±-Ketoamides Based upon the Acylation of Anions Derived from Cyanomethylamines Followed by Oxidative Cleavageâ€. Organic Letters, 2002, 4, 1103-1105.	4.6	59
219	The synthesis and structureâ€"activity relationships of 1,3-diaryl 1,2,4-(4 H)-triazol-5-ones: A new class of calcium-dependent, large conductance, potassium (maxi-k) channel opener targeted for urge urinary incontinence. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1117-1120.	2.2	35
220	The synthesis and characterization of BMS-204352 (MaxiPostâ„¢) and related 3-fluorooxindoles as openers of maxi-K potassium channels. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1023-1026.	2.2	161
221	Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 3129-3133.	2.2	39
222	Structureâ€"activity relationships for a series of thiobenzamide influenza fusion inhibitors derived from 1,3,3-Trimethyl-5-hydroxy-cyclohexylmethylamine. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 3379-3382.	2.2	51
223	The mono-functionalization of symmetrical polyamines. Tetrahedron, 2002, 58, 3111-3128.	1.9	58
224	A Strategy for the Synthesis of Aryl Î±â€Ketoamides Based upon the Acylation of Anions Derived from Cyanomethylamines Followed by Oxidative Cleavage.. ChemInform, 2002, 33, 58-58.	0.0	0
225	Structureâ€"activity relationship studies of a bisbenzimidazole-based, Zn2+-dependent inhibitor of HCV NS3 serine protease. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2355-2359.	2.2	39
226	An approach to the identification of potent inhibitors of influenza virus fusion using parallel synthesis methodology. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2393-2396.	2.2	29
227	Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nature Medicine, 2001, 7, 471-477.	30.7	295
228	Drug discoverers â€" you need us! â€" Reply. Drug Discovery Today, 2001, 6, 664-665.	6.4	2
229	Salicylamide inhibitors of influenza virus fusion. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 1649-1652.	2.2	22
230	HIV-1 entry â€" an expanding portal for drug discovery. Drug Discovery Today, 2000, 5, 183-194.	6.4	71
231	Respiratory syncytial virus: recent progress towards the discovery of effective prophylactic and therapeutic agents. Drug Discovery Today, 2000, 5, 241-252.	6.4	33
232	Corrigendum. Drug Discovery Today, 2000, 5, 285.	6.4	0
233	Regioselective Monobenzoylation of Unsymmetrical Piperazines. Journal of Organic Chemistry, 2000, 65, 4740-4742.	3.2	17
234	Selective benzoylation of primary amines in the presence of secondary amines. Tetrahedron Letters, 1999, 40, 6745-6747.	1.4	13

#	Article	IF	Citations
235	Solid-phase synthesis of benzisothiazolones as serine protease inhibitors. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 663-666.	2.2	13
236	Novel quinolizidine salicylamide influenza fusion inhibitors. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 2177-2180.	2.2	17
237	Synthesis of3H-labeled 2-hydroxy-N-[(1,3,3-trimethyl-[4,5,6-3H]cyclohexyl)methyl]-5-azidobenzamide, a photoaffinity analog of an influenza fusion inhibitor. Journal of Labelled Compounds and Radiopharmaceuticals, 1999, 42, 965-974.	1.0	2
238	Stereoselective reduction via lithium borotritide: synthesis of3H-labeled 2-hydroxy-N-[(5-hydroxy-[5-3H]-1,3,3-trimethylcyclohexyl)methyl]-5-methylbenzamide. Journal of Labelled Compounds and Radiopharmaceuticals, 1999, 42, 1061-1068.	1.0	1
239	Benzoylation of Dianions:Â Preparation of Monobenzoylated Derivatives of Symmetrical Secondary Diamines. Journal of Organic Chemistry, 1999, 64, 7661-7662.	3.2	35
240	pH-Dependent Changes in Photoaffinity Labeling Patterns of the H1 Influenza Virus Hemagglutinin by Using an Inhibitor of Viral Fusion. Journal of Virology, 1999, 73, 1785-1794.	3.4	35
241	A facile construction of 4-hydroxymethylbenzisothiazolone-1,1-dioxide. Tetrahedron Letters, 1998, 39, 1483-1486.	1.4	22
242	A synthesis of 4-thiomethylbenzisothiazolone-1,1-dioxide using HDPT. Tetrahedron Letters, 1998, 39, 5309-5312.	1.4	10
243	1,2-Benzisothiazol-3-one 1,1-Dioxide Inhibitors of Human Mast Cell Tryptase. Journal of Medicinal Chemistry, 1998, 41, 4854-4860.	6.4	52
244	[3-[4-(4,5-diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (BMY 45778) is a potent non-prostanoid prostacyclin partial agonist: Effects on platelet aggregation, adenylyl cyclase, cAMP levels, protein kinase, and iloprost binding. Prostaglandins, 1997, 53, 21-35.	1.2	38
245	The discovery of novel openers of Ca2+-dependent large-conductance potassium channels: Pharmacophore search and physiological evaluation of flavonoids. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 759-762.	2.2	21
246	DISCOVERY OF A NOVEL CLASS OF BK CHANNEL OPENERS: ENANTIOSPECIFIC SYNTHESIS AND BK CHANNEL OPENING ACTIVITY OF 3-(5-CHLORO-2-HYDROXYPHENYL)-1,3-DIHYDRO-3-HYDROXY-6-(TRIFLUOROMETHYL)-2H-INDOL-2-ONE. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 1255-1260.	2.2	82
247	Taking aim at a moving target-inhibitors of influenza virus Part 1 : virus adsorption, entry and uncoating. Drug Discovery Today, 1996, 1, 316-324.	6.4	28
248	Taking aim at a moving target â€" inhibitors of influenza virus Part 2: viral replication, packaging and release. Drug Discovery Today, 1996, 1, 388-397.	6.4	29
249	N-Benzylated benzimidazol-2-one derivatives: activators of large-conductance Ca2+-dependent K+ channels. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 1641-1646.	2.2	25
250	3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 499-504.	2.2	18
251	Identification of N-Hydroxamic Acid and N-Hydroxyimide Compounds that Inhibit the Influenza Virus Polymerase. Antiviral Chemistry and Chemotherapy, 1996, 7, 353-360.	0.6	55
252	BMY 42393, An Orally Active Prostacyclin Partial Agonist Of Novel Structure. Cardiovascular Drug Reviews, 1995, 13, 289-304.	4.1	2

#	Article	IF	Citations
253	Azetidin-2-one derivatives as inhibitors of thrombin. Bioorganic and Medicinal Chemistry, 1995, 3, 1123-1143.	3.0	152
254	Active site-directed thrombin inhibitors-II. Studies related to arginine/guanidine bioisosteres. Bioorganic and Medicinal Chemistry, 1995, 3, 1145-1156.	3.0	18
255	Regiospecific Functionalization of 1,3-Dihydro-2H-benzimidazol-2-one and Structurally Related Cyclic Urea Derivatives. Journal of Organic Chemistry, 1995, 60, 1565-1582.	3.2	49
256	Opening of large-conductance calcium-activated potassium channels by the substituted benzimidazolone NS004. Journal of Neurophysiology, 1994, 71, 1873-1882.	1.8	63
257	Synthesis of 3-Hydroxypyrimidine-2,4-diones. Addition of Anilines to Benzyloxy Isocyanate Synthons to GiveN-Hydroxyureas. Synthesis, 1994, 1994, 846-850.	2.3	15
258	A general method for the synthesis of isatins: Preparation of regiospecifically functionalized isatins from anilines. Tetrahedron Letters, 1994, 35, 7303-7306.	1.4	58
259	2-[3-[2-(4,5-diphenyl-2-oxazolyl) ethyl] phenoxy] acetic acid (BMY 42393): A new, structurally-novel Thrombosis Research, 1994, 74, 115-123.	1.7	14
260	animal models of arterial thrombosis. Thrombosis Research, 1994, 74, 125-133.	1.7	4
261	Non-prostanoid prostacyclin mimetics. Drugs of the Future, 1994, 19, 361.	0.1	47
262	Synthesis and excitatory amino acid pharmacology of some novel quinoxalinediones. Bioorganic and Medicinal Chemistry Letters, 1993, 3, 2801-2804.	2.2	25
263	Nonprostanoid prostacyclin mimetics. 5. Structure-activity relationships associated with [3-[4-(4,5-diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid. Journal of Medicinal Chemistry, 1993, 36, 3884-3903.	6.4	50
264	Active site-directed synthetic thrombin inhibitors: synthesis, in vitro and in vivo activity profile of BMY 44621 and analogs. An examination of the role of the amino group in the D-Phe-Pro-Arg-H series. Journal of Medicinal Chemistry, 1993, 36, 300-303.	6.4	48
265	Inhibitors of blood platelet cAMP phosphodiesterase. 4. Structural variation of the side-chain terminus of water-soluble 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives. Journal of Medicinal Chemistry, 1993, 36, 3251-3264.	6.4	20
266	Nonprostanoid prostacyclin mimetics. 4. Derivatives of 2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid substituted .alpha. to the oxazole ring. Journal of Medicinal Chemistry, 1993, 36, 3871-3883.	6.4	23
267	Patent Update: Modulators of Excitatory Amino Acids: Patent Activity June 1991 to June 1992. Current Opinion in Therapeutic Patents, 1992, 2, 1251-1259.	0.0	0
268	Inhibitors of blood platelet cAMP phosphodiesterase. 3. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives with enhanced aqueous solubility. Journal of Medicinal Chemistry, 1992, 35, 2688-2696.	6.4	11
269	Inhibitors of blood platelet cAMP phosphodiesterase. 2. Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains. Journal of Medicinal Chemistry, 1992, 35, 2672-2687.	6.4	15
270	Nonprostanoid prostacyclin mimetics. 3. Structural variations of the diphenyl heterocycle moiety. Journal of Medicinal Chemistry, 1992, 35, 3498-3512.	6.4	29

#	Article	IF	Citations
271	Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic. Journal of Medicinal Chemistry, 1992, 35, 389-397.	6.4	33
272	Nonprostanoid prostacyclin mimetics. 2. 4,5-diphenyloxazole derivatives.. Journal of Medicinal Chemistry, 1992, 35, 3483-3497.	6.4	32
273	1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones - inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. Journal of Medicinal Chemistry, 1991, 34, 2906-2916.	6.4	36
274	Antithrombotic activity of BMY-43351, a new imidazoquinoline with enhanced aqueous solubility. Thrombosis Research, 1991, 63, 145-155.	1.7	5
275	Imidazoquinoline derivatives: Potent inhibitors of platelet cAMP phosphodiesterase which elevate cAMP levels and activate protein kinase in platelets. Thrombosis Research, 1991, 62, 31-42.	1.7	24
276	Diethyl 2,4-dioxoimidazolidine-5-phosphonates: Horner-Wadsworth-Emmons reagents for the mild and efficient preparation of C-5 unsaturated hydantoin derivatives. Journal of Organic Chemistry, 1991, 56, 6897-6904.	3.2	64
277	Utilization of Sulfoximines in the Synthesis of Optically Pure Substances. Phosphorous and Sulfur and the Related Elements, 1985, 24, 151-163.	0.2	7
278	Alkenyl sulphoxides as precursors to cyclopentenones and prostanoid Î²-side chains. Tetrahedron Letters, 1983, 24, 405-408.	1.4	14
279	Preparation and reactions of sulfonimidoyl fluorides. Journal of Organic Chemistry, 1983, 48, 1-3.	3.2	65
280	Ketone methylenation with optical resolution. Synthesis of (+)- and (â^')-hop ether. Tetrahedron Letters, 1982, 23, 5005-5008.	1.4	26
281	Ketone methylenation with optical resolution. Total synthesis of the ginseng sesquiterpene (-)-.beta.-panasinsene and its enantiomer. Journal of the American Chemical Society, 1981, 103, 7667-7669.	13.7	47
282	Reaction of allylsulphenic acid with alkynes to give thiolan 1-oxide derivatives. Tetrahedron Letters, 1980, 21, 4379-4382.	1.4	10
283	Ligandâ€Enabled Î²â€C(sp ³)â^'H Lactamization of Tosylâ€Protected Aliphatic Amides Using a Practical Oxidant. Angewandte Chemie, 0, , .	2.0	2